CN Patent

CN100542530C — 3′－[(2z)－[1－(3,4－二甲基苯基)－1,5－二氢－3－甲基－5－氧代－4h－吡唑－4－亚基]肼基]－2′－羟基－[ 1,1′－联苯基]－3－羧酸二－(单乙醇胺)

Assigned to Novartis AG · Expires 2009-09-23 · 17y expired

What this patent protects

本发明涉及一种改进的血小板生成素类似物，其为3’-[(2Z)-[1-(3，4-二甲基苯基)-1，5-二氢-3-甲基-5-氧代-4H-吡唑-4-亚基]肼基]-2’-羟基-[1，1’-联苯基]-3-羧酸二-(单乙醇胺)盐。

USPTO Abstract

本发明涉及一种改进的血小板生成素类似物，其为3’-[(2Z)-[1-(3，4-二甲基苯基)-1，5-二氢-3-甲基-5-氧代-4H-吡唑-4-亚基]肼基]-2’-羟基-[1，1’-联苯基]-3-羧酸二-(单乙醇胺)盐。

Drugs covered by this patent

eltrombopag-olamine (ELTROMBOPAG OLAMINE)

Patent Metadata

Patent number: CN100542530C
Jurisdiction: CN
Classification: —
Expires: 2009-09-23
Drug substance claim: No
Drug product claim: No
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.